BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.

doi:10.1158/1078-0432.CCR-19-3579

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2020

Middleton Gary, Yang Yiqun, Campbell Catarina D, André Thierry, Atreya Chloe E, Schellens Jan H M, Yoshino Takayuki, Bendell Johanna C, Hollebecque Antoine, McRee Autumn J, Siena Salvatore, Gordon Michael S, Tabernero Josep, Yaeger Rona, O'Dwyer Peter J, De Vos Filip, Van Cutsem Eric, Millholland John M, Brase Jan C, Rangwala Fatima, Gasal Eduard, Corcoran Ryan B

Abstract excerpt

PURPOSE: The influence of the transcriptional and immunologic context of mutations on therapeutic outcomes with targeted therapy in cancer has not been well defined. BRAF V600E-mutant (BM) colorectal cancer comprises two main transcriptional subtypes, BM1 and BM2. We sought to determine the impact of BM subtype, as well as distinct biological features of those subtypes, on response to BRAF/MEK/EGFR inhibition in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to MAP Kinase Kinase 1

Share to Oximes

Share to Panitumumab

Share to Pyridones

Share to Pyrimidinones

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 32047001
DOI: 10.1158/1078-0432.CCR-19-3579
PMCID: PMC8194012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.PMID 32047001Read ↗

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.Semantic proximity Read ↗

Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancerSemantic proximity Read ↗

Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancerSemantic proximity Read ↗

Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapySemantic proximity Read ↗

Advances in immunotyping of colorectal cancerSemantic proximity Read ↗

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.Semantic proximity Read ↗

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.Semantic proximity Read ↗

Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity.Semantic proximity Read ↗

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF V600-mutated Metastatic MelanomaSemantic proximity Read ↗

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.Semantic proximity Read ↗

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerSemantic proximity Read ↗

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.